Biomarkers of body iron stores and risk of developing type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 11, Issue 5, 2009, Pages 472-479

  Rajpathak, Swapnil ^a   Wylie Rosett, J ^a   Gunter, M J ^a   Negassa, A ^a   Kabat, G C ^a   Rohan, T E ^a   Crandall, J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Ferritin; Transferrin receptors; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; FERRITIN; GLUCOSE; INSULIN; IRON; TRANSFERRIN RECEPTOR;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PATHOGENESIS; PREDICTION; RISK ASSESSMENT; TURBIDIMETRY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FERRITINS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; IRON; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; RECEPTORS, TRANSFERRIN; RISK ASSESSMENT; UNITED STATES;

EID: 84878635879     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00985.x     Document Type: Article

References (70)

1. Puntarulo S. Iron, oxidative stress and human health. Mol Aspects Med 2005; 26: 299-312.
2. Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 2003; 533: 153-171.
3. Nelson RL. Iron and colorectal cancer risk: Human studies. Nutr Rev 2001; 59: 140-148.
4. Sullivan JL. Iron and coronary heart disease. Iron makes myocardium vulnerable to ischemia. BMJ 1993; 307: 1066-1067.
5. Ascherio A, Willett WC. Are body iron stores related to the risk of coronary heart disease? N Engl J Med 1994; 330: 1152-1154.
6. Ma J, Stampfer MJ. Body iron stores and coronary heart disease. Clin Chem 2002; 48: 601-603.
7. Alpert PT. New and emerging theories of cardiovascular disease: infection and elevated iron. Biol Res Nurs 2004; 6: 3-10.
8. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002; 51: 2348-2354.
9. Hernandez C, Lecube A, Carrera A, Simo R. Soluble transferrin receptors and ferritin in type 2 diabetic patients. Diabet Med 2005; 22: 97-101.
10. Ramakrishnan U, Kuklina E, Stein AD. Iron stores and cardiovascular disease risk factors in women of reproductive age in the United States. Am J Clin Nutr 2002; 76: 1256-1260.
11. Sheu WH, Chen YT, Lee WJ, Wang CW, Lin LY. A relationship between serum ferritin and the insulin resistance syndrome is present in non-diabetic women but not in non-diabetic men. Clin Endocrinol (Oxf) 2003; 58: 380-385.
12. Tuomainen TP, Nyyssonen K, Salonen R et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men. Diabetes Care 1997; 20: 426-428.
13. Hua NW, Stoohs RA, Facchini FS. Low iron status and enhanced insulin sensitivity in lacto-ovo vegetarians. Br J Nutr 2001; 86: 515-519.
14. Tilbrook L. Cross talk between iron metabolism and diabetes. Ann Clin Biochem 2004; 41 (Pt 3): 255.
15. Piperno A, Trombini P, Gelosa M et al. Increased serum ferritin is common in men with essential hypertension. J Hypertens 2002; 20: 1513-1518.
16. Halle M, Konig D, Berg A, Keul J, Baumstark MW. Relationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease. Atherosclerosis 1997; 128: 235-240.
17. Williams MJ, Poulton R, Williams S. Relationship of serum ferritin with cardiovascular risk factors and inflammation in young men and women. Atherosclerosis 2002; 165: 179-184.
18. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004; 27: 2422-2428.
19. Fernandez-Real JM, Ricart-Engel W, Arroyo E et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998; 21: 62-68.
20. Escobar-Morreale HF, Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Sancho J, San Millan JL. Body iron stores are increased in overweight and obese women with polycystic ovary syndrome. Diabetes Care 2005; 28: 2042-2044.
21. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Sanchon R, San Millan JL, Escobar-Morreale HF. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 2007; 30: 2309-2313.
22. Gillum RF. Association of serum ferritin and indices of body fat distribution and obesity in Mexican American men -the Third National Health and Nutrition Examination Survey. Int J Obes Relat Metab Disord 2001; 25: 639-645.
23. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 1999; 22: 1978-1983.
24. Eshed I, Elis A, Lishner M. Plasma ferritin and type 2 diabetes mellitus: A critical review. Endocr Res 2001; 27: 91-97.
25. Dinneen SF, O'Mahony MS, O'Brien T, Cronin CC, Murray DM, O'Sullivan DJ. Serum ferritin in newly diagnosed and poorly controlled diabetes mellitus. Ir J Med Sci 1992; 161: 636-638.
26. Salonen JT, Tuomainen TP, Nyyssonen K, Lakka HM, Punnonen K. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ 1998; 317: 727.
27. Jehn ML, Guallar E, Clark JM et al. A prospective study of plasma ferritin level and incident diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2007; 165: 1047-1054.
28. Forouhi NG, Harding AH, Allison M et al. Elevated serum ferritin levels predict new-onset type 2 diabetes: Results from the EPIC-Norfolk prospective study. Diabetologia 2007; 50: 949-956.
29. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004; 291: 711-717.
30. Ren Y, Tian H, Li X, Liang J, Zhao G. Elevated serum ferritin concentrations in a glucose-impaired population and in normal glucose tolerant first-degree relatives in familial type 2 diabetic pedigrees 10.2337/diacare.27.2.622. Diabetes Care 2004; 27: 622-623.
31. Fernandez-Real JM, Moreno JM, Lopez-Bermejo A, Chico B, Vendrell J, Ricart W. Circulating soluble transferrin receptor according to glucose tolerance status and insulin sensitivity. Diabetes Care 2007; 30: 604-608.
32. Ponka P, Beaumont C, Richardson DR. Function and regulation of transferrin and ferritin. Semin Hematol 1998; 35: 35-54.
33. Ponka P, Lok CN. The transferrin receptor: Role in health and disease. Int J Biochem Cell Biol 1999; 31: 1111-1137.
34. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999; 22: 623-634.
35. The Diabetes Prevention Program: Baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care 2000; 23: 1619-1629.
36. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
37. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
38. Prentice R, Breslow N. Retrospective studies and failure time models. Biometrika 1978; 65: 153-158.
39. Kriska A, Caspersen C. Introduction to a collection of physical activity questionnaires. Med Sci Sports Exerc 1997; 29 (Suppl): S5-S9.
40. Sung KC, Kang JH, Shin HS. Relationship of cardiovascular risk factors and serum ferritin with C-reactive protein. Arch Med Res 2007; 38: 121-125.
41. Fumeron F, Pean F, Driss F et al. Ferritin and transferrin are both predictive of the onset of hyperglycemia in men and women over 3 years: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes Care 2006; 29: 2090-2094.
42. Powell LW. Diagnosis of hemochromatosis. Semin Gastrointest Dis 2002; 13: 80-88.
43. Simon M, Vongsavanthong S, Jehan JP, Roussey M, Bourel M. [Diabetes and hemochromatosis. II. Diabetes of idiopathic hemochromatosis and common diabetes. Apropos of 130 personal cases of hemochromatosis]. Sem Hop 1973; 49: 2133-2141.
44. Simon M, Vongsavanthong S, Hespel JP, Lecornu M, Bourel M, [Diabetes and hemochromatosis. I. Diabetes in idiopathic hemochromatosis. Apropos of 130 personal cases of hemochromatosis]. Sem Hop 1973; 49: 2125-2132.
45. Worwood M, Cragg SJ, Jacobs A, McLaren C, Ricketts C, Economidou J. Binding of serum ferritin to concanavalin A: Patients with homozygous beta thalassaemia and transfusional iron overload. Br J Haematol 1980; 46: 409-416.
46. Scriver CR. The Metabolic & Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 2001.
47. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003; 5: 18-25.
48. Acton RT, Barton JC, Passmore LV et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 2006; 29: 2084-2089.
49. Fernandez-Real JM, Vendrell J, Baiget M, Gimferrer E, Ricart W. C282Y and H63D mutations of the hemochromatosis candidate gene in type 2 diabetes. Diabetes Care 1999; 22: 525-526.
50. Guillygomarc'h A, Mendler MH, Moirand R et al. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001; 35: 344-349.
51. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: Effects on insulin sensitivity and beta-cell function. Diabetes 2002; 51: 1000-1004.
52. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Lopez-Bermejo A, Ricart W. Blood letting in high-ferritin type 2 diabetes: Effects on vascular reactivity. Diabetes Care 2002; 25: 2249-2255.
53. Thomas MC, MacIsaac RJ, Tsalamandris C, Jerums G. Elevated iron indices in patients with diabetes. Diabet Med 2004; 21: 798-802.
54. Kaye TB, Guay AT, Simonson DC. Non-insulin-dependent diabetes mellitus and elevated serum ferritin level. J Diabetes Complications 1993; 7: 246-249.
55. Hughes K, Choo M, Kuperan P, Ong CN, Aw TC. Cardiovascular risk factors in non-insulin-dependent diabetics compared to non-diabetic controls: A population-based survey among Asians in Singapore. Atherosclerosis 1998; 136: 25-31.
56. Wolff SP. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993; 49: 642-652.
57. Ferrannini E. Insulin resistance, iron, and the liver. Lancet 2000; 355: 2181-2182.
58. Niederau C, Berger M, Stremmel W et al. Hyperinsulinaemia in non-cirrhotic haemochromatosis: Impaired hepatic insulin degradation? Diabetologia 1984; 26: 441-444.
59. Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF. Potential role of increased iron stores in diabetes. Am J Med Sci 2003; 325: 332-339.
60. Green A, Basile R, Rumberger JM. Transferrin and iron induce insulin resistance of glucose transport in adipocytes. Metabolism 2006; 55: 1042-1045.
61. Mainous AG 3rd, Wells BJ, Everett CJ, Gill JM, King DE. Association of ferritin and lipids with C-reactive protein. Am J Cardiol 2004; 93: 559-562.
62. Torti SV, Torti FM. Iron and ferritin in inflammation and cancer. Adv Inorg Biochem 1994; 10: 119-137.
63. Cotton F, Thiry P, Boeynaems J. Measurement of soluble transferrin receptor by immunoturbidimetry and immunonephelometry. Clin Biochem 2000; 33: 263-267.
64. Sherwood RA, Pippard MJ, Peters TJ. Iron homeostasis and the assessment of iron status. Ann Clin Biochem 1998; 35 (Pt 6): 693-708.
65. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998; 44: 45-51.
66. Chang J, Bird R, Clague A, Carter A. Clinical utility of serum soluble transferrin receptor levels and comparison with bone marrow iron stores as an index for iron-deficient erythropoiesis in a heterogeneous group of patients. Pathology 2007; 39: 349-353.
67. Malope BI, MacPhail AP, Alberts M, Hiss DC. The ratio of serum transferrin receptor and serum ferritin in the diagnosis of iron status. Br J Haematol 2001; 115: 84-89.
68. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997; 89: 1052-1057.
69. Davis RJ, Corvera S, Czech MP. Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 1986; 261: 8708-8711.
70. Clairmont KB, Czech MP. Insulin injection increases the levels of serum receptors for transferrin and insulin-like growth factor-II/ mannose-6-phosphate in intact rats. Endocrinology 1990; 127: 1568-1573.